Research Analysts Set Expectations for Agios Pharmaceuticals Inc’s Q3 2018 Earnings (AGIO)
Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Stock analysts at Leerink Swann issued their Q3 2018 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Monday, September 24th. Leerink Swann analyst A. Berens forecasts that the biopharmaceutical company will earn ($1.80) per share for the quarter. Leerink Swann currently has a “Market Perform” rating and a $80.00 price target on the stock. Leerink Swann also issued estimates for Agios Pharmaceuticals’ Q4 2018 earnings at ($1.85) EPS, FY2018 earnings at ($6.57) EPS, FY2019 earnings at ($7.13) EPS and FY2020 earnings at ($6.21) EPS.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.62) by $0.43. The business had revenue of $40.40 million for the quarter, compared to the consensus estimate of $12.47 million. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The company’s quarterly revenue was up 257.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.78) EPS.
Agios Pharmaceuticals stock opened at $75.89 on Thursday. Agios Pharmaceuticals has a fifty-two week low of $51.62 and a fifty-two week high of $99.82.
In other news, Director John Maraganore sold 13,555 shares of the company’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total value of $986,126.25. Following the sale, the director now owns 38,609 shares in the company, valued at $2,808,804.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $83.50, for a total value of $250,500.00. Following the completion of the sale, the insider now owns 60,196 shares in the company, valued at approximately $5,026,366. The disclosure for this sale can be found here. Insiders sold 28,627 shares of company stock worth $2,212,296 in the last 90 days. Company insiders own 3.02% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Woodford Investment Management Ltd purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth about $32,849,000. Barrett Asset Management LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth approximately $253,000. Principal Financial Group Inc. boosted its position in Agios Pharmaceuticals by 11.5% during the first quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock worth $1,218,000 after purchasing an additional 1,533 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Agios Pharmaceuticals by 32.7% during the second quarter. State of Alaska Department of Revenue now owns 5,960 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 1,470 shares in the last quarter. Finally, NewSquare Capital LLC purchased a new position in Agios Pharmaceuticals during the second quarter worth approximately $182,000. Hedge funds and other institutional investors own 93.63% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.